Efficacy of Early Multimodal Physiotherapy in Patients With Reverse Shoulder Prosthesis
Launched by UNIVERSITY OF MALAGA · Apr 4, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of an early treatment program that combines different physiotherapy techniques to help patients who have received a reverse shoulder prosthesis, which is a type of artificial shoulder joint. The goal is to see if this program, which focuses on exercises to improve strength and movement, can lead to better recovery results for these patients. Researchers will gather information through questionnaires and various tests that measure strength, movement, and muscle health.
To participate in this study, you need to be an adult between the ages of 18 and 90 who has had a reverse shoulder prosthesis and can provide signed consent to join. Unfortunately, people with other upper limb injuries or those who face language barriers that prevent understanding the study cannot participate. If you join the trial, you can expect to take part in a structured exercise program and help shape new treatment protocols for future patients with similar conditions. This study is not yet recruiting participants, but it aims to improve recovery methods for shoulder surgery patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults with a reverse shoulder prosthesis.
- • Age between 18 and 90 years.
- • Signed informed consent.
- Exclusion Criteria:
- • Language or cultural barriers.
- • Other upper limb injury.
- • Treatment that affect physical activity capacity.
About University Of Malaga
The University of Malaga, a leading academic institution in Spain, is committed to advancing medical research and improving patient outcomes through innovative clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise in various fields, including medicine, health sciences, and biotechnology, to conduct rigorous studies. The institution is dedicated to fostering a culture of ethical research practices and ensuring the highest standards of safety and efficacy in its clinical trials, ultimately contributing to the development of groundbreaking therapies and enhancing the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported